Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics
September 29 2016 - 12:00AM
Business Wire
Companies Collaborate in Their Aim to
Accelerate Accurate Diagnosis of Cancer for Patients in
China
Agilent Technologies Inc. (NYSE:A) and Burning Rock today
announced they have signed an agreement under which Burning Rock
will develop cancer diagnostics in China based on the Agilent
SureSelect target enrichment system.
Agilent is the leading provider of target enrichment for
next-generation DNA sequencing. Target enrichment saves researchers
time and resources by enabling them to focus on regions of interest
rather than looking at the entire genome. Burning Rock is a
fast-growing company focused on developing cancer diagnostics based
on DNA sequencing.
“As the leader in molecular cancer diagnosis in China, Burning
Rock is very pleased to partner with Agilent, a global leader in
diagnostics and genomics,” said Yusheng Han, the founder and chief
executive officer of Burning Rock. “Collaboration between our two
companies will provide additional high-quality molecular diagnostic
solutions based on next-generation sequencing, including
non-invasive testing, relapse monitoring, early-stage diagnosis and
cancer susceptibility.”
Fast and accurate cancer diagnoses are becoming increasingly
important in China, with its extensive population and growing focus
on advancing human health.
“We are excited to partner with Burning Rock to accelerate
accurate diagnosis of cancer for patients in China,” said Jacob
Thaysen, president of Agilent’s Diagnostics and Genomics Group. “We
believe that target enrichment and next-generation sequencing have
a vital role to play in personalizing medicine and ultimately
delivering treatments tailored to the individual. This is
especially so for complex diseases such as cancer.”
Burning Rock plans to register its molecular diagnostic kit with
the China Food and Drug Administration. The company believes the
kit could become the first CFDA-approved capture sequencing-based
cancer diagnostic assay in the Chinese market.
About Burning Rock
Burning Rock is headquartered in Beijing, China, and is a
diagnostics company committed to the field of molecular testing to
improve oncology patients’ individualized treatment guidance. It
offers research and commercialized clinical laboratory services
mainly through bioinformatics on next-generation sequencing
platforms. Burning Rock has a state-of-the-art molecular and
pathological examination platform and has developed a series of
testing solutions. To learn more, visit www.brbiotech.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in
life sciences, diagnostics and applied chemical markets, is the
premier laboratory partner for a better world. Agilent works with
customers in more than 100 countries, providing instruments,
software, services and consumables for the entire laboratory
workflow. The company generated revenue of $4.04 billion in fiscal
2015 and employs about 12,000 people worldwide. Information about
Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160928005037/en/
Agilent Technologies, Inc.Victoria Wadsworth-Hansen, +1
408-553-2005+45 2933
6980victoria.wadsworth-hansen@agilent.comorBurning RockPan
Yingying, +86 21 6029 3721yingying.pan@brbiotech.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024